SDZNY OTC
Sandoz Group AG
1W: -3.6%
1M: +3.5%
3M: -3.3%
YTD: +14.4%
1Y: +73.5%
$82.01
-1.47 (-1.76%)
Weekly Expected Move ±5.4%
$74
$79
$83
$88
$92
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$35.5B
52W Range48.055-94.15
Volume1,208
Avg Volume29,517
Beta0.53
Dividend$1.03
Analyst Ratings
Company Info
CEORichard Saynor
Employees22,049
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2023-10-04
Websitesandoz.com
Suurstoffi 14
Rotkreuz 6343
CH
Rotkreuz 6343
CH
41 61 324 11 11
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
Latest News
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Buy: Here's What You Should Know
USNA or SDZNY: Which Is the Better Value Stock Right Now?
Jazz, AstraZeneca, Astellas: Foreign Healthcare's strongest Quant picks
Canada approves generic version of Novo's Ozempic
Amneal 2026-2027 Upside From Biosimilars Scale
Recent Insider Trades
No insider trades found